Current treatment of metastatic bladder cancer and future directions. - Wikidata - wikimedia - TriplyDB

Current treatment of metastatic bladder cancer and future directions.

Current treatment of metastatic bladder cancer and future directions.

http://www.wikidata.org/entity/Q37960909

about

Targeting Hsp90 in urothelial carcinoma Synthetic miRNA-mowers targeting miR-183-96-182 cluster or miR-210 inhibit growth and migration and induce apoptosis in bladder cancer cells.Genetic polymorphisms modify bladder cancer recurrence and survival in a USA population-based prognostic study.Hedyotis diffusa plus Scutellaria barbata Induce Bladder Cancer Cell Apoptosis by Inhibiting Akt Signaling Pathway through Downregulating miR-155 Expression.Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.Urinary bladder cancer in dogs, a naturally occurring model for cancer biology and drug development.An enhanced hTERT promoter-driven CRISPR/Cas9 system selectively inhibits the progression of bladder cancer cells.Synthetic miRNA sponges driven by mutant hTERT promoter selectively inhibit the progression of bladder cancer.Nuclease and anti-proliferative activities of copper(II) complexes of N3O tripodal ligands involving a sterically hindered phenolate.

P2860

Q27023406-87B36889-A382-40B7-AB08-FC413DE25133 Q34533542-496166C8-4D94-4CA4-9614-5CC8DB78CDD1 Q35944928-9E0EA309-E285-44D6-A8C3-7F3BFF60B780 Q36637505-D41174EF-F3B0-4ADA-8BD0-1F8738CAB2C8 Q36817080-B7D334A2-2379-4387-9760-5FB6836E848C Q38220806-FC3F07DA-F6D2-4151-8C52-80DE87AAA1DA Q38681698-BD703FAA-E87B-461D-821A-D296D2DB2D95 Q38899341-0D25C51E-15E3-4239-90FB-7D825B38E824 Q39159203-90B1A86C-272F-4F96-B73C-EB905389B75B

P2860

Current treatment of metastatic bladder cancer and future directions.

http://www.wikidata.org/entity/Q37960909

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Current treatment of metastatic bladder cancer and future directions.

@en

Current treatment of metastatic bladder cancer and future directions.

@nl

type

label

Current treatment of metastatic bladder cancer and future directions.

@en

Current treatment of metastatic bladder cancer and future directions.

@nl

prefLabel

Current treatment of metastatic bladder cancer and future directions.

@en

Current treatment of metastatic bladder cancer and future directions.

@nl

P1433

Q37960909-98A42EF3-69EE-4B54-89C8-DA6B8DF2671C

P1476

Q37960909-68E78E99-AAAE-4C33-91BE-EDEE23FC754C

P2093

Q37960909-71F10B89-D5A1-44EC-8029-A2D1EAF79B01

Q37960909-92783B53-DB90-4A19-B8A3-E4E39425955A

Q37960909-A13B262E-3FBB-4C92-A430-7003BC6767FB

P2860

Q37960909-06C59798-19EF-4C28-9345-0BF32E530F11

Q37960909-09C37BEE-7173-4947-A245-77972F43508A

Q37960909-111F22E1-E93C-4C7B-8414-27624466B3AC

Q37960909-14ACD062-B065-459C-A856-0F60BD13C732

Q37960909-1C8EE29A-C0A7-45C7-8141-78995C070C1D

Q37960909-215BE031-BA8D-474E-B9E9-D7C50350CF9D

Q37960909-234D2560-9A47-44EB-ACAB-AC85A7B2E1EE

Q37960909-28A80DB5-0089-46E2-9FE5-C49464CEE37E

Q37960909-2D4ADDD0-8286-424B-8F4D-ED7C14513914

Q37960909-32A6D768-D518-495D-AC65-6667700BEA89

P304

Q37960909-804C0373-6BEF-4858-B3CD-5A03AC63809D

P31

Q37960909-0BDAE997-66E9-45CA-9A6F-A2FC23EAAF94

P356

Q37960909-4923CA29-70C9-4D21-A29E-FA8F4725B098

P433

Q37960909-19AF1F07-4455-4A37-BE04-5755CFDD213B

P478

Q37960909-A3464819-0C26-4BE5-827A-2636B79C1992

P577

Q37960909-A6F4D322-65BE-47BF-8017-3653A1BF13F0

P698

Q37960909-3D5029EB-04D5-4273-A73F-A2A4C1D7D373

P356

P1433

Expert Review of Anticancer Therapy

P1476

Current treatment of metastatic bladder cancer and future directions.

@en

P2093

Amy Q Lei

http://www.w3.org/2001/XMLSchema#string

Chong-xian Pan

http://www.w3.org/2001/XMLSchema#string

Liang Cheng

http://www.w3.org/2001/XMLSchema#string

P2860

Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells

Cancer statistics, 2010

A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium

Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study.

Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group.

Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group.

Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study.

Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen.

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.

Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule?

P304

1851-1862

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERA.11.181

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22117153

http://www.w3.org/2001/XMLSchema#string